期刊文献+

358例肺癌患者K-ras基因的突变分析 被引量:1

Analysis of K-ras gene mutation in 358 cases of lung cancer
下载PDF
导出
摘要 目的分析358例肺癌患者K-ras基因突变的突变情况,为肺癌患者的个体化治疗提供指导。方法通过嵌套和低变性温度下的复合PCR(COLD-PCR)-测序法分析358例肺癌患者K-ras基因突变状态。结果在358例肺癌患者中,K-ras基因总体突变率为8.10%。94份血浆标本、250份肿瘤组织标本、14份胸腔积液及腹水标本中的突变率分别为2.13%、9.60%、7.14%。突变类型包括G12C、G12D、G12A、G12V、G13D、Q61H,3种不同标本之间K-ras基因的突变率比较,差异无统计学意义(P=0.064 8);男性与女性患者的突变率分别为6.96%、8.59%,差异无统计学意义(P=0.574 0);30-〈45岁、45-〈60岁、大于或等于60岁患者中的突变率分别为4.76%、5.34%、9.22%,不同年龄段患者K-ras基因的突变率比较,差异无统计学意义(P=0.250 3)。结论肺癌患者K-ras基因突变类型主要为G12C、G12D、G12V、G13D,K-ras基因在不同标本类型、不同性别、不同年龄之间的突变率无明显差异。 Objective To analyze the mutation situation of K-ras gene in 358 cases of lung cancer to provide the guidance for the personalized therapy of lung cancer. Methods The nested and low denatured temperature compound PCR(COLD-PCR) method was used to analyze the K-ras mutations situation in 358 patients with lung cancer. Results In 358 lung cancer patients, the total mutation frequency of K-ras gene was 8.10%. The mutation rates were 2.13% in 94 plasma samples,9.60% in 250 tumor tissue samples and 7.14% in 14 pleural and ascites samples. The mutation types included G12C,G12D,G12A,G12V,G13I) and Q61H,the mutation rate had no statistical difference among 3 kinds of samples (P=0. 064 8);the mutation rate was 6.96% in male patients and 8.59 % in female patients,the difference was not statistically significant(P=0. 574 0);the mutation rates were 4.76% in the patients aged 30-〈45 years old,5.34% in the patients aged 45-〈60 years old and 9.22% in the patients aged ≥60 years old, the differences were not statistically significant (P=0.250 3). Conclusion The mutation types of K-ras gene are mainly G12C, G12D,G12V and G13D. The mutation rate of K-ras gene has no significant differences among different types of sample,different genders and different ages.
作者 卢丽琴 李纲
出处 《国际检验医学杂志》 CAS 2016年第3期321-323,共3页 International Journal of Laboratory Medicine
关键词 肺癌 K-RAS基因 基因突变状态 lung cancer K-ras gene mutation status
  • 相关文献

参考文献15

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [J]. CA Cancer J Clin, 2009,59 (4) : 225-249.
  • 2Paz-Ares LG,De Marinis F,Dediu M,et al. Paramount:final over- all survival results of the phase Ⅲ study of maintenance peme- trexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small- cell lung cancer[J]. J Clin 0ncol,2013,31(23):2895-2902.
  • 3Dacic S, Flanagan M, Cieply K, et al. Signiicance of EGFR prote expression and gene ampliication in non-small cell lung carcinoma [J]. Am J Clin Pathol,2006,125(6) :860-865.
  • 4Dziadziuszko R,Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression,gene dosage,and ge- fitinib sensitivity in non-small cell lung cancer[J]. Clin Cancer Res,2006,12(10):3078-3084.
  • 5Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer[J]. J Carcinog, 2013,67 (22):257- 274.
  • 6Sergina NV, Moasser MM. The HER family and cancer:emerging molecular mechanisms and therapeutic targets[J]. Trends Mol Med, 2007,13(12): 527-534.
  • 7Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches[J]. J Thorac On- col,2012,7(2) :306-315.
  • 8Hiltermann TJ, Pore MM, van den Berg A, et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor[J]. Ann Oncol, 2012,23 (11) : 2937-2942.
  • 9Hou JM,Krebs MG,Lancashire L,et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer[J]. J Clin Oncol,2012,30(5) :525-532.
  • 10Otto WR. Lung epithelial stem cells[J]. J Pathol, 2002,197(4) : 527-535.

同被引文献10

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部